Kenneth S. Suslick

Ken Suslick received his B.S. from the California Institute of Technology in 1974, his Ph.D. from Stanford University in 1978, and then came to the University of Illinois, where he is now the Marvin T. Schmidt Research Professor of Chemistry. He and his research group have published more than 500 scientific publications, edited four books, and holds 71 patents and patent applications.

Suslick's three major research areas are the chemical effects of ultrasound (which includes nano-materials synthesis and sonoluminescence), the mechanochemistry of inorganic solids (including shock wave energy dissipation by MOFs, i.e., metal-organic framework solids) and chemical sensing (specifically, our optoelectronic nose, i.e., colorimetric sensor arrays for the detection of VOCs). The latter project in artificial olfaction and molecular recognition is an exciting spinoff of our earlier work on the bioinorganic and materials chemistry of metalloporphyrins.

In addition to his academic research, Suslick has had significant entrepreneurial experience. He was the lead consultant for Molecular Biosystems Inc. and part of the team that commercialized the first echo contrast agent for medical sonography, Albunex™, which became Optison™ by GE Healthcare. In addition, he was the founding consultant for VivoRx Pharmaceuticals and co-inventor of one of the first FDA-approved nanopharmacueticals, Abraxane™ (serum albumin microspheres with a paclitaxel core), which is the predominant current delivery system for taxol chemotherapy for breast cancer; VivoRx became Abraxis Bioscience, which was acquired by Celgene for $2.9 billion. Most recently, Suslick invented, developed, and commercialized the "optoelectronic nose", a simple but highly effective technology for the identification and quantification of gas analytes. This has found important applications in the detection of toxic gases and explosives, the discrimination among complex odorants, and rapid diagnosis of disease based on their smell.